The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Avidity Biosciences Inc (NASDAQ: RNA) was $30.98 for the day, down -2.27% from the previous closing price of $31.70. In other words, the price has decreased by -$2.27 from its previous closing price. On the day, 1.52 million shares were traded.
Ratios:
Our analysis of RNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 16.91 and its Current Ratio is at 16.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $70.
On March 12, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $72.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $70 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 01 ’25 when Gallagher Kathleen P. sold 5,875 shares for $32.40 per share. The transaction valued at 190,324 led to the insider holds 50,554 shares of the business.
KATHLEEN GALLAGHER bought 5,875 shares of RNA for $191,819 on May 01 ’25. On Apr 01 ’25, another insider, Gallagher Kathleen P., who serves as the Chief Program Officer of the company, sold 5,875 shares for $27.83 each. As a result, the insider received 163,486 and left with 50,554 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 418.17 while its Price-to-Book (P/B) ratio in mrq is 2.81.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 5.28%, while the 200-Day Moving Average is calculated to be -14.32%.
Shares Statistics:
A total of 120.51M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 8.88% of the company’s shares, while institutions hold 107.70% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 13.0 analysts. The consensus estimate for the next quarter is -$1.02, with high estimates of -$0.61 and low estimates of -$1.47.
Analysts are recommending an EPS of between -$2.71 and -$5.36 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$4.43, with 14.0 analysts recommending between -$2.65 and -$5.64.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $13.18M, while the lowest revenue estimate was $1.6M, resulting in an average revenue estimate of $7.39M. In the same quarter a year ago, actual revenue was $10.9M
